Large-scale AI service in insurer health management.
AI NEWS
Past AI News
Chinese and English are the same day. This page lists every item, each with the original link, the author, and the engagement.
This day
October 28, 2026
5 items for 2026-10-28, ranked by combined engagement.
Top 3
Shifts AI due-diligence burden to hospitals.
A vendor opening eval data to governance teams.
All
UnitedHealthcare expands AI assistant Avery to 21M members, saying ~90% of interactions need no human rep
Large-scale AI service in insurer health management.
CollapseUnitedHealthcare expands AI assistant Avery to 21M members, saying ~90% of interactions need no human rep
Health AI Navigator relays that UnitedHealthcare is expanding its AI assistant Avery to 21 million members to answer insurance questions on benefits, deductibles, provider networks, claims and costs. UnitedHealthcare says around 90% of interactions are resolved without a human representative. The poster sees repetitive admin queries as a good fit but questions how "resolved" is measured—accuracy, satisfaction, or users simply leaving. The 90% is company-reported; methodology not stated.
HHS HTI-5 rule drops the requirement for certified EHR developers to provide standardized model-card info for some predictive CDS tools
Shifts AI due-diligence burden to hospitals.
CollapseHHS HTI-5 rule drops the requirement for certified EHR developers to provide standardized model-card info for some predictive CDS tools
Health AI Navigator says the US removed certain AI transparency requirements from its health IT certification program: under HTI-5, certified EHR developers no longer must provide standardized model-card information for certain predictive clinical decision-support tools. That information was meant to help providers understand how models were developed, evaluated and monitored, including risks and limits. HHS says the change reduces burden and encourages innovation. The poster argues it shifts more responsibility onto hospitals to obtain that information (opinion); see the HHS/ASTP rule text for specifics.
Abridge October release: 9 capabilities incl. in-visit orders in Epic, outpatient CDI queries and an Evaluation Dashboard for governance teams
A vendor opening eval data to governance teams.
CollapseAbridge October release: 9 capabilities incl. in-visit orders in Epic, outpatient CDI queries and an Evaluation Dashboard for governance teams
Abridge's October "Now in Practice" adds nine capabilities, most moving post-visit work back into the encounter. The blog lists In-Visit Orders staged in Epic as they're discussed for clinicians to review and sign; Query Engine extended to outpatient visits with AHIMA/ACDIS-compliant CDI queries inside the note; and one-click inpatient diagnosis write-back to the chart. For AI governance and clinical informatics leaders, a new Evaluation Dashboard in the Enterprise Portal shows evaluation results by product with methodology, refresh cadence and known limitations, linking model cards. Outcomes are vendor-reported.
FDA-cleared SimBioSys TumorSight Risk uses pre-op breast MRI plus pathology to estimate 5- and 10-year recurrence risk
Imaging AI moving from diagnosis to prognosis.
CollapseFDA-cleared SimBioSys TumorSight Risk uses pre-op breast MRI plus pathology to estimate 5- and 10-year recurrence risk
NVIDIA highlighted SimBioSys's TumorSight Risk, an FDA-cleared tool powered by NVIDIA technology that analyzes an existing breast MRI alongside pathology and clinical information to estimate five- and ten-year recurrence risk. It targets HR-positive, HER2-negative early-stage breast cancer, with results available before surgery to inform treatment discussions. No accuracy figures were given. The post drew about 500 likes and 78k views.
Health AI funding week: ~$392M across 11 companies, led by Warp Sciences' $215M
Where capital is going: admin, benefits, drug R&D.
CollapseHealth AI funding week: ~$392M across 11 companies, led by Warp Sciences' $215M
Healthcare AI Guy's weekly recap: about $392M raised across 11 health AI companies. The largest was AI drug-discovery firm Warp Sciences at $215M, followed by patient advocacy Baba ($40M Series A), health-benefits AI Avante ($30M Series A), clinical search Vera Health ($28.5M Series A) and healthcare admin ClarityCare ($16.3M Series A), among others. On M&A it lists Redesign Health + ARC Global at a ~$2B combined valuation. A personal roundup; check each company's announcement.